Equities

Arcellx Inc

ACLX:NSQ

Arcellx Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)87.22
  • Today's Change0.00 / 0.00%
  • Shares traded324.14k
  • 1 Year change+68.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy6
Outperform13
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Arcellx Inc have a median target of 114.00, with a high estimate of 134.00 and a low estimate of 73.00. The median estimate represents a 30.70% increase from the last price of 87.22.
High53.6%134.00
Med30.7%114.00
Low-16.3%73.00

Earnings history & estimates in USD

On Nov 07, 2024, Arcellx Inc reported 3rd quarter 2024 losses of -0.48 per share.
The next earnings announcement is expected on Mar 17, 2025.
Average growth rate-129.20%
Arcellx Inc reported annual 2023 losses of -1.47 per share on Feb 28, 2024.
Average growth rate+84.06%
More ▼

Revenue history & estimates in USD

Arcellx Inc had 3rd quarter 2024 revenues of 26.03m. This missed the 34.37m consensus estimate of the 13 analysts following the company. This was 45.32% above the prior year's 3rd quarter results.
Average growth rate+62.29%
Arcellx Inc had revenues for the full year 2023 of 110.32m.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.